Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

BACKGROUND Poor engraftment due to low cell doses restricts the usefulness of umbilical-cord-blood transplantation. We hypothesized that engraftment would be improved by transplanting cord blood that was expanded ex vivo with mesenchymal stromal cells. METHODS We studied engraftment results in 31 adults with hematologic cancers who received transplants of 2 cord-blood units, 1 of which contained cord blood that was expanded ex vivo in cocultures with allogeneic mesenchymal stromal cells. The results in these patients were compared with those in 80 historical controls who received 2 units of unmanipulated cord blood. RESULTS Coculture with mesenchymal stromal cells led to an expansion of total nucleated cells by a median factor of 12.2 and of CD34+ cells by a median factor of 30.1. With transplantation of 1 unit each of expanded and unmanipulated cord blood, patients received a median of 8.34×10(7) total nucleated cells per kilogram of body weight and 1.81×10(6) CD34+ cells per kilogram--doses higher than in our previous transplantations of 2 units of unmanipulated cord blood. In patients in whom engraftment occurred, the median time to neutrophil engraftment was 15 days in the recipients of expanded cord blood, as compared with 24 days in controls who received unmanipulated cord blood only (P<0.001); the median time to platelet engraftment was 42 days and 49 days, respectively (P=0.03). On day 26, the cumulative incidence of neutrophil engraftment was 88% with expansion versus 53% without expansion (P<0.001); on day 60, the cumulative incidence of platelet engraftment was 71% and 31%, respectively (P<0.001). CONCLUSIONS Transplantation of cord-blood cells expanded with mesenchymal stromal cells appeared to be safe and effective. Expanded cord blood in combination with unmanipulated cord blood significantly improved engraftment, as compared with unmanipulated cord blood only. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00498316.).

[1]  E. Shpall,et al.  Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. , 2012, Experimental hematology.

[2]  E. Freireich,et al.  Twenty-five years of peripheral blood stem cell transplantation. , 2011, Blood.

[3]  Colleen Delaney,et al.  Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. , 2010, Blood.

[4]  S. Parmar,et al.  Umbilical cord blood transplantation. , 2010, Clinical advances in hematology & oncology : H&O.

[5]  J. Wagner,et al.  Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. , 2010, The Lancet. Oncology.

[6]  Colleen Delaney,et al.  Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution , 2010, Nature Medicine.

[7]  I. Kerridge,et al.  Single versus double unrelated umbilical cord blood units for allogeneic transplantation in adults with advanced haematological malignancies: a retrospective comparison of outcomes , 2009, Internal medicine journal.

[8]  J. Sampath,et al.  Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. , 2009, Blood.

[9]  D. Weisdorf,et al.  Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  M. Gobbi,et al.  Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. , 2008, The Lancet. Oncology.

[11]  A. Nagler,et al.  Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial , 2008, Bone Marrow Transplantation.

[12]  E. Shpall,et al.  Efficacy of ‘Off-the-Shelf’, Commercially-Available, Third-Party Mesenchymal Stem Cells (MSC) in Ex Vivo Cord Blood (CB) Co-Culture Expansion. , 2007 .

[13]  P. Thall,et al.  Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP). , 2007 .

[14]  E. Gluckman,et al.  Outcomes of transplantation in children with acute leukaemia , 2007, The Lancet.

[15]  T. Witte.  Stem Cell transplantation (SCT) for MDS. , 2007 .

[16]  J. Damen,et al.  Hematopoietic colony-forming cell assays. , 2007, Methods in molecular biology.

[17]  Juliet N Barker,et al.  Umbilical Cord Blood (UCB) transplantation: an alternative to the use of unrelated volunteer donors? , 2007, Hematology. American Society of Hematology. Education Program.

[18]  E. Shpall,et al.  Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells , 2006, Bone Marrow Transplantation.

[19]  J. Dick,et al.  Dynamic changes in cellular and microenvironmental composition can be controlled to elicit in vitro human hematopoietic stem cell expansion. , 2005, Experimental hematology.

[20]  Todd E DeFor,et al.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. , 2005, Blood.

[21]  E. Gluckman,et al.  History of the clinical use of umbilical cord blood hematopoietic cells. , 2005, Cytotherapy.

[22]  Cindy L. Miller,et al.  Human and mouse hematopoietic colony-forming cell assays. , 2005, Methods in molecular biology.

[23]  M. Labopin,et al.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. , 2004, The New England journal of medicine.

[24]  E. Shpall,et al.  Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. , 2004, Cytotherapy.

[25]  A. McWhinnie,et al.  Unrelated umbilical cord blood transplants in adults: Early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. , 2003, Experimental hematology.

[26]  S. Karandish,et al.  Double‐chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units , 2002, British journal of haematology.

[27]  Chan Zeng,et al.  Transplantation of ex vivo expanded cord blood. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  E. Gluckman.  Hematopoietic stem-cell transplants using umbilical-cord blood. , 2001, The New England journal of medicine.

[29]  J. Wagner,et al.  Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. , 2001, The New England journal of medicine.

[30]  J. Wagner,et al.  Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. , 2001, The New England journal of medicine.

[31]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[32]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[33]  I. Mcniece,et al.  Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells. , 1997, Journal of hematotherapy.

[34]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[35]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[36]  P. Simmons,et al.  CD34 expression by stromal precursors in normal human adult bone marrow. , 1991, Blood.

[37]  P. Simmons,et al.  Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. , 1991, Blood.